2-chloromethyl-3-ethyl-4-oxo-3,4-dihydro-quinazoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloromethyl-3-ethyl-4-oxo-3,4-dihydro-quinazoline
• 英文别名: 2-(chloromethyl)-3-ethyl-4(3H)-quinazolinone；2-(chloromethyl)-3-ethylquinazolin-4-one
• 化学式: C₁₁H₁₁ClN₂O
• 分子量: 222.674
• InChiKey: QTERTLJOGOZFCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloromethyl-3-ethyl-4-oxo-3,4-dihydro-quinazoline 、 2-巯基苯并噻唑 在 四丁基溴化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以82%的产率得到2-((benz[d]thiazol-2-ylthio)methyl)-3-ethylquinazolin-4(3H)-one
  参考文献：
  名称：

  Rafeeq, Md.; Reddy, Ch. Venkata Ramana; Dubey, Indian Journal of Heterocyclic Chemistry, 2015, vol. 24, # 4, p. 405 - 410

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(2-氯乙酰基氨基)-苯甲酰胺 在 四丁基溴化铵 、 potassium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-chloromethyl-3-ethyl-4-oxo-3,4-dihydro-quinazoline
  参考文献：
  名称：

  Rafeeq, Md.; Reddy, Ch. Venkata Ramana; Dubey, Indian Journal of Heterocyclic Chemistry, 2015, vol. 24, # 4, p. 405 - 410

  摘要：

  DOI：

文献信息

• [EN] BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE POUR TRAITER DES TROUBLES INDUITS PAR GLYTL
  申请人：GLAXO GROUP LTD

  公开号：WO2011012622A1

  公开（公告）日：2011-02-03

  The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

  本发明涉及苯并噁唑酮衍生物，其制备方法，含有它们的药物组合物和药物，以及它们在治疗由GlyT1介导的疾病中的应用，包括神经系统和神经精神疾病，特别是精神病、痴呆或注意力缺陷障碍。
• Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
  申请人：Dr. Reddy's Research Foundation

  公开号：US06310069B1

  公开（公告）日：2001-10-30

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

  本发明涉及新型抗糖尿病化合物及其互变异构体、衍生物、立体异构体、多晶形态、药用可接受盐、药用可接受溶剂和含有它们的药用可接受组合物。本发明特别涉及一般式(I)的新型噁唑烷二酮衍生物及其药用可接受盐、药用可接受溶剂和含有它们的药用组合物。
• Heterocyclic compounds, process for their preparation and pharmaceutical
  申请人：Dr. Reddy's Research Foundation

  公开号：US05885997A1

  公开（公告）日：1999-03-23

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

  本发明涉及新型抗糖尿病化合物，它们的互变异构形式，它们的衍生物，它们的立体异构体，它们的多晶形态，它们的药学上可接受的盐，它们的药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。本发明特别涉及一般式（I）的新型噁唑烷二酮衍生物，以及它们的药学上可接受的盐、药学上可接受的溶剂和含有它们的药用组合物。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES, LEUR PROCEDE DE PREPARATION, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET UTILISATION DE CES COMPOSES DANS LE TRAITEMENT DU DIABETE ET DES MALADIES ASSOCIEES
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：WO1997041097A2

  公开（公告）日：1997-11-06

  (EN) The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.(FR) La présente invention se rapporte à des nouveaux composés antidiabétiques, aux formes tautomères, aux dérivés, aux stéréo-isomères et aux polymorphes de ces composés, aux sels et aux solvates de ces composés, acceptables sur le plan pharmacologique, ainsi qu'aux compositions les contenant et acceptables sur le plan pharmaceutique. L'invention concerne notamment des nouveaux dérivés azolidinediones de la formule générale (I), ainsi que les sels et solvates de ceux-ci, acceptables sur le plan pharmacologique, et les compositions pharmaceutiques contenant ces dérivés.

  本发明涉及新型抗糖尿病化合物、它们的互变异构体、它们的衍生物、它们的立体异构体、它们的多晶形态、它们的药学上可接受的盐、它们的药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明特别涉及一般式(I)的新型噁唑烷二酮衍生物及其药学上可接受的盐、药学上可接受的溶剂和含有它们的制药组合物。
• Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
  申请人：DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC.

  公开号：US20010031759A1

  公开（公告）日：2001-10-18

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. 1

  本发明涉及一种新型抗糖尿病化合物，其互变异构体、衍生物、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化合物以及含有它们的药学上可接受的组合物。本发明特别涉及一种一般式（I）的新型噁唑烷二酮衍生物及其药学上可接受的盐、药学上可接受的溶剂化合物和含有它们的药物组合物。1